Stock events for Becton, Dickinson & Co. (BDX)
Several events impacted BDX's stock in the past six months. BD held its Q4 FY25 and Q1 FY26 earnings conference calls. An investor update announced the intent to combine Waters and BD's Biosciences & Diagnostics Business. Despite better-than-expected Q4 CY2025 results, the stock plunged due to management's cautious outlook. A dividend of $1.05 per share was announced, effective March 10, 2026. BD secured CE Mark approval in the European Union for its Revello Vascular Covered Stent, but shares traded flat. Overall, the share price of BDX declined by 23.48% from March 5, 2025, to March 4, 2026.
Demand Seasonality affecting Becton, Dickinson & Co.’s stock price
Demand for Becton, Dickinson & Co.'s products and services can exhibit some seasonality. The Integrated Diagnostic Solutions business unit experienced a dampening in its fiscal first-quarter performance due to comparisons with the prior-year respiratory season, but benefited from strong performance in BD's Microbiology platforms. The BD Medical segment sees support from demand for biologics and GLP-1 products, while the BD Life Sciences segment benefits from new assays and approvals, though it faces ongoing pressures from the Chinese market and funding. Analysts anticipate some demand challenges, with revenue growth projected to decelerate over the next 12 months.
Overview of Becton, Dickinson & Co.’s business
Becton, Dickinson & Co. (BDX), also known as BD, is an American multinational medical technology company operating in the medical technology sector. It develops, manufactures, and sells medical devices, instrument systems, and reagents, and offers consulting and analytics services. BD operates through three segments: BD Medical, which focuses on medication delivery and management; BD Life Sciences, dedicated to diagnostics and research; and BD Interventional, specializing in minimally invasive surgical and interventional procedures.
BDX’s Geographic footprint
Becton, Dickinson & Co. serves a global market, operating in more than 190 countries worldwide. The company's headquarters are located in Franklin Lakes, New Jersey, U.S..
BDX Corporate Image Assessment
Becton, Dickinson & Co. has maintained a positive brand reputation, marked by innovation and product advancements. BD pioneered a new standard in surgical safety with the FDA-cleared Surgiphor 1000mL and launched the Urine Complete Cup Kit. The company secured CE Mark approval in the European Union for its Revello Vascular Covered Stent. BD was named to Fortune's 2024 list of America's Most Innovative Companies.
Ownership
Becton, Dickinson & Co.'s ownership is predominantly held by institutional investors, who collectively own over 90% of the company's stock. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. Individual investors and other public entities also hold shares, while insiders own about 0.66% of the shares.
